{"id":62390,"date":"2026-04-04T21:48:52","date_gmt":"2026-04-04T13:48:52","guid":{"rendered":"https:\/\/flcube.com\/?p=62390"},"modified":"2026-04-04T21:48:53","modified_gmt":"2026-04-04T13:48:53","slug":"merck-launches-pivotal-phase-2b-3-trial-for-mk-8748-bispecific-antibody-in-wet-amd-treatment","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=62390","title":{"rendered":"Merck Launches Pivotal Phase 2b\/3 Trial for MK-8748 Bispecific Antibody in Wet AMD Treatment"},"content":{"rendered":"\n<p><strong>Merck &amp; Co., Inc.<\/strong> (MSD, <a href=\"https:\/\/www.google.com\/finance\/quote\/MRK:NYSE\">NYSE: MRK<\/a>) announced the initiation of a <strong>pivotal Phase 2b\/3 clinical trial<\/strong> evaluating <strong>MK-8748<\/strong> (also known as <strong>Tiespectus<\/strong>, <strong>EYE201<\/strong>) for the treatment of <strong>neovascular (wet) age-related macular degeneration (NVAMD)<\/strong>. The investigational therapy represents a novel <strong>bispecific antibody<\/strong> with a dual mechanism targeting both the <strong>Tie2 pathway<\/strong> and <strong>VEGF inhibition<\/strong>.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-clinical-development-framework\">Clinical Development Framework<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Item<\/th><th>Detail<\/th><\/tr><\/thead><tbody><tr><td><strong>Company<\/strong><\/td><td>Merck &amp; Co., Inc. (MSD)<\/td><\/tr><tr><td><strong>Stock Code<\/strong><\/td><td>NYSE: MRK<\/td><\/tr><tr><td><strong>Investigational Drug<\/strong><\/td><td>MK-8748 (Tiespectus, EYE201)<\/td><\/tr><tr><td><strong>Drug Class<\/strong><\/td><td>Bispecific antibody<\/td><\/tr><tr><td><strong>Primary Indication<\/strong><\/td><td>Neovascular (wet) age-related macular degeneration (NVAMD)<\/td><\/tr><tr><td><strong>Trial Name<\/strong><\/td><td>MALBEC<\/td><\/tr><tr><td><strong>Trial Phase<\/strong><\/td><td>Phase 2b\/3 (pivotal)<\/td><\/tr><tr><td><strong>ClinicalTrials.gov ID<\/strong><\/td><td>NCT07496567<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-mechanism-of-action-amp-innovation-profile\">Mechanism of Action &amp; Innovation Profile<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Dual-Target Approach:<\/strong> MK-8748 simultaneously <strong>activates the Tie2 pathway<\/strong> and <strong>inhibits VEGF<\/strong>, addressing two key pathological mechanisms in wet AMD<\/li>\n\n\n\n<li><strong>Therapeutic Goal:<\/strong> Stabilize retinal and choroidal blood vessels while reducing fluid accumulation in the macula<\/li>\n\n\n\n<li><strong>Differentiation:<\/strong> Unlike current anti-VEGF monotherapies, MK-8748&#8217;s bispecific design targets vascular destabilization at its source through Tie2 activation<\/li>\n\n\n\n<li><strong>Development Strategy:<\/strong> Part of a broader late-phase development program with a second NVAMD study scheduled to begin later this year<\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-supporting-clinical-evidence-phase-1-2a-rioja-trial\">Supporting Clinical Evidence \u2013 Phase 1\/2a RIOJA Trial<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Study Component<\/th><th>Patient Population<\/th><th>Key Findings<\/th><\/tr><\/thead><tbody><tr><td><strong>Phase 1\/2a RIOJA<\/strong><\/td><td>NVAMD patients<\/td><td>Demonstrated proof-of-concept for dual mechanism efficacy<\/td><\/tr><tr><td><strong>Phase 1\/2a RIOJA<\/strong><\/td><td>Macular edema secondary to BRVO<\/td><td>Established safety profile across multiple retinal conditions<\/td><\/tr><tr><td><strong>Phase 1\/2a RIOJA<\/strong><\/td><td>Diabetic macular edema (DME)<\/td><td>Confirmed target engagement and biological activity<\/td><\/tr><tr><td><strong>ClinicalTrials.gov ID<\/strong><\/td><td>NCT06664502<\/td><td>Two-part study design supporting pivotal advancement<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<p>The positive results from the RIOJA trial provided the foundation for Merck&#8217;s decision to advance MK-8748 into pivotal development, representing a significant milestone in the company&#8217;s ophthalmology pipeline.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-market-context-amp-strategic-implications\">Market Context &amp; Strategic Implications<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Wet AMD Market:<\/strong> Current standard of care relies heavily on frequent anti-VEGF injections, creating substantial unmet need for more durable and comprehensive treatment approaches<\/li>\n\n\n\n<li><strong>Competitive Landscape:<\/strong> MK-8748&#8217;s dual mechanism could differentiate it from existing anti-VEGF therapies and emerging combination approaches<\/li>\n\n\n\n<li><strong>Commercial Potential:<\/strong> Successful development would position Merck to capture significant share in the $10+ billion global wet AMD market<\/li>\n\n\n\n<li><strong>Pipeline Diversification:<\/strong> Strengthens Merck&#8217;s presence in ophthalmology beyond its established therapeutic areas<\/li>\n<\/ul>\n\n\n\n<p><strong>Forward-Looking Statements<\/strong><br>This brief contains forward-looking statements regarding Merck&#8217;s clinical development plans, regulatory timelines, and commercial expectations for MK-8748. Actual results may differ materially due to risks including clinical trial outcomes, regulatory approvals, competitive dynamics, and market adoption.<a href=\"https:\/\/flcube.com\/\">-Fineline Info &amp; Tech<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Merck &amp; Co., Inc. (MSD, NYSE: MRK) announced the initiation of a pivotal Phase 2b\/3&#8230;<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7,11],"tags":[62,2675,176,903,44],"class_list":["post-62390","post","type-post","status-publish","format-standard","hentry","category-company","category-drug","tag-clinical-trial-approval-initiation","tag-merck-sharp-dohme","tag-msd","tag-nyse-mrk","tag-ophthalmology"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v23.6 (Yoast SEO v27.3) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>Merck Launches Pivotal Phase 2b\/3 Trial for MK-8748 Bispecific Antibody in Wet AMD Treatment - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"Merck &amp; Co., Inc. (MSD, NYSE: MRK) announced the initiation of a pivotal Phase 2b\/3 clinical trial evaluating MK-8748 (also known as Tiespectus, EYE201) for the treatment of neovascular (wet) age-related macular degeneration (NVAMD). The investigational therapy represents a novel bispecific antibody with a dual mechanism targeting both the Tie2 pathway and VEGF inhibition.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=62390\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Merck Launches Pivotal Phase 2b\/3 Trial for MK-8748 Bispecific Antibody in Wet AMD Treatment\" \/>\n<meta property=\"og:description\" content=\"Merck &amp; Co., Inc. (MSD, NYSE: MRK) announced the initiation of a pivotal Phase 2b\/3 clinical trial evaluating MK-8748 (also known as Tiespectus, EYE201) for the treatment of neovascular (wet) age-related macular degeneration (NVAMD). The investigational therapy represents a novel bispecific antibody with a dual mechanism targeting both the Tie2 pathway and VEGF inhibition.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=62390\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2026-04-04T13:48:52+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-04-04T13:48:53+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"2560\" \/>\n\t<meta property=\"og:image:height\" content=\"1894\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=62390#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=62390\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"Merck Launches Pivotal Phase 2b\\\/3 Trial for MK-8748 Bispecific Antibody in Wet AMD Treatment\",\"datePublished\":\"2026-04-04T13:48:52+00:00\",\"dateModified\":\"2026-04-04T13:48:53+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=62390\"},\"wordCount\":402,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"keywords\":[\"Clinical trial approval \\\/ initiation\",\"Merck Sharp &amp; Dohme\",\"MSD\",\"NYSE: MRK\",\"Ophthalmology\"],\"articleSection\":[\"Company\",\"Drug\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=62390#respond\"]}],\"copyrightYear\":\"2026\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=62390\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=62390\",\"name\":\"Merck Launches Pivotal Phase 2b\\\/3 Trial for MK-8748 Bispecific Antibody in Wet AMD Treatment - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"datePublished\":\"2026-04-04T13:48:52+00:00\",\"dateModified\":\"2026-04-04T13:48:53+00:00\",\"description\":\"Merck & Co., Inc. (MSD, NYSE: MRK) announced the initiation of a pivotal Phase 2b\\\/3 clinical trial evaluating MK-8748 (also known as Tiespectus, EYE201) for the treatment of neovascular (wet) age-related macular degeneration (NVAMD). The investigational therapy represents a novel bispecific antibody with a dual mechanism targeting both the Tie2 pathway and VEGF inhibition.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=62390#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=62390\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=62390#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Merck Launches Pivotal Phase 2b\\\/3 Trial for MK-8748 Bispecific Antibody in Wet AMD Treatment\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Merck Launches Pivotal Phase 2b\/3 Trial for MK-8748 Bispecific Antibody in Wet AMD Treatment - Insight, China&#039;s Pharmaceutical Industry","description":"Merck & Co., Inc. (MSD, NYSE: MRK) announced the initiation of a pivotal Phase 2b\/3 clinical trial evaluating MK-8748 (also known as Tiespectus, EYE201) for the treatment of neovascular (wet) age-related macular degeneration (NVAMD). The investigational therapy represents a novel bispecific antibody with a dual mechanism targeting both the Tie2 pathway and VEGF inhibition.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=62390","og_locale":"en_US","og_type":"article","og_title":"Merck Launches Pivotal Phase 2b\/3 Trial for MK-8748 Bispecific Antibody in Wet AMD Treatment","og_description":"Merck & Co., Inc. (MSD, NYSE: MRK) announced the initiation of a pivotal Phase 2b\/3 clinical trial evaluating MK-8748 (also known as Tiespectus, EYE201) for the treatment of neovascular (wet) age-related macular degeneration (NVAMD). The investigational therapy represents a novel bispecific antibody with a dual mechanism targeting both the Tie2 pathway and VEGF inhibition.","og_url":"https:\/\/flcube.com\/?p=62390","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2026-04-04T13:48:52+00:00","article_modified_time":"2026-04-04T13:48:53+00:00","og_image":[{"width":2560,"height":1894,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","type":"image\/jpeg"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=62390#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=62390"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"Merck Launches Pivotal Phase 2b\/3 Trial for MK-8748 Bispecific Antibody in Wet AMD Treatment","datePublished":"2026-04-04T13:48:52+00:00","dateModified":"2026-04-04T13:48:53+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=62390"},"wordCount":402,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"keywords":["Clinical trial approval \/ initiation","Merck Sharp &amp; Dohme","MSD","NYSE: MRK","Ophthalmology"],"articleSection":["Company","Drug"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=62390#respond"]}],"copyrightYear":"2026","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=62390","url":"https:\/\/flcube.com\/?p=62390","name":"Merck Launches Pivotal Phase 2b\/3 Trial for MK-8748 Bispecific Antibody in Wet AMD Treatment - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"datePublished":"2026-04-04T13:48:52+00:00","dateModified":"2026-04-04T13:48:53+00:00","description":"Merck & Co., Inc. (MSD, NYSE: MRK) announced the initiation of a pivotal Phase 2b\/3 clinical trial evaluating MK-8748 (also known as Tiespectus, EYE201) for the treatment of neovascular (wet) age-related macular degeneration (NVAMD). The investigational therapy represents a novel bispecific antibody with a dual mechanism targeting both the Tie2 pathway and VEGF inhibition.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=62390#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=62390"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=62390#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"Merck Launches Pivotal Phase 2b\/3 Trial for MK-8748 Bispecific Antibody in Wet AMD Treatment"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/62390","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=62390"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/62390\/revisions"}],"predecessor-version":[{"id":62391,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/62390\/revisions\/62391"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=62390"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=62390"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=62390"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}